INTRODUCTION:
The CCB verapamil is clinically effective in the treatment of HTSs when injected intralesionally.
1, 2 We developed a novel treatment based on the topical application of a silicone gel sheet (SGS) containing verapamil microparticles. The ability of these SGSs to inhibit hypertrophic scar (HTS) formation in a rabbit ear wound model was examined.
MATERIALS AND METHODS:
Ten New Zealand White (NZW) rabbits with a total of 80 wounds in both ears were used in this study. The rabbits were divided into five groups (control, SGS, and SGS+0.25, 2.5, and 25 mg verapamil/g). Histopathologic findings were quantified based on the scar elevation index (SEI) and fibroblast and capillary counts.
RESULTS:
The mean SEI, fibroblast counts, and capillary counts differed significantly among the five groups (P < 0.05). The median SEI was significantly lower in the SGS+2.5 mg verapamil/g group (Figure 1 ) than in the SGS group (Figure 2 ) (1.2 vs. 2.2). The median number of fibroblasts was significantly lower in the SGS+0.25 mg verapamil/g group than in the SGS group (172.5 vs. 243). The median number of capillary lumina was significantly higher in the untreated control group (29.5) whereas there was no significant difference between the SGS group and the SGS+0.25, SGS+2.5, and SGS+25 mg verapamil/g groups (28.5, 18, 20, and 18, respectively).
CONCLUSION:
Topical application of SGS with verapamil microparticles may be a novel, effective treatment method for HTS but its safety and efficacy in humans must be tested in clinical trials.
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